Encouragingly, epalrestat, an AKR1B1 inhibitor already approved for diabetic neuropathy treatment, effectively mitigated drug resistance in both in vitro and in vivo HCC models. This evidence concerns the gene AKR1B1 and diabetic neuropathy.